Skip to main content
    Neuralink

    Neuralink

    Late Stage · Wholesale investors only

    Series E (Jun 2025)

    $650M

    In trials (Jan 2026)

    21

    In daily use

    20+

    Cursor control

    10+ bits/s

    Figures from Neuralink's own updates (2 Jun 2025 and 28 Jan 2026) and careers page. Funding rounds are historical events, not an offer price.

    Historical events, not an offer price

    Financing milestones

    1. 1Jul 2021

      Series C funding round

      $205M

      Led by Vy Capital

    2. 2Aug 2023

      Series D funding round

      $280M

      Led by Founders Fund

    3. 3Jun 2025

      Series E funding round

      $650M

      Participation from key investors including ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners, Vy Capital, amongst others

    Understand and expand consciousness

    Neuralink’s mission

    About Neuralink

    In its own words: “Neuralink is building brain-computer interfaces (BCI) that will return autonomy to people with unmet medical needs.” Its stated mission is to “understand and expand consciousness”.

    Company Highlights

    • $650M Series E funding round in Jun 2025, after a $280M Series D in Aug 2023 (led by Founders Fund) and a $205M Series C in Jul 2021 (led by Vy Capital).
    • 21 trial participants as of Jan 2026, from three participants in 2024 to multiple participants per month in 2025.
    • 20+ implants in daily use; cursor control by thought at 10+ bits/s.
    • Participant typing speed of up to 40 words per minute.
    • Device-control studies PRIME, CAN-PRIME, GB-PRIME and UAE-PRIME, listed under United States, Canada, Great Britain and Rest of World.

    Source: Neuralink updates (29 Jul 2021, 7 Aug 2023, 2 Jun 2025 and 28 Jan 2026 posts), careers and clinical-trials pages.

    Licence Notice: Managed Investment Scheme (AFSL 416956)

    www.investingplatform.com.au is operated by Figure 8 Capital Pty Ltd. Any information contained in this communication is general advice only and does not take into account your individual financial situation, investment objectives, or needs. It does not constitute personal financial advice. Before making any investment decision, you should consider whether this information is appropriate for your circumstances and obtain independent financial, legal, and tax advice.

    This offer/service is available to wholesale clients only, within the meaning of section 761G of the Corporations Act 2001 (Cth). If you are not a wholesale client, you should not act on this information. If you are uncertain whether you qualify as a wholesale client, you should obtain independent legal advice before proceeding.

    SpringCapital Secondary Fund is an unregistered managed investment scheme. Investor invests in the SpringCapital Secondary Fund which has exposure to an investment in Neuralink. Figure 8 Capital Pty Ltd (CAR No. 001311723) and Mondari Capital Advisors Pty Ltd (CAR No. 01318060) are Corporate Authorised Representatives of Alpha Node Advisors Pty Ltd (AFSL 416956) (ANA). Under that licence they arrange for wholesale clients to apply for units in the Fund and provide general advice about it. They do not issue or operate the Fund, do not hold your money or units, and are not the Issuer. None of ANA, Figure 8 Capital or Mondari Capital Advisors guarantees the performance of the Fund or the return of your capital. Refer to the Information Memorandum for the formal offer of the product.

    An investment in any managed investment scheme arranged by Figure 8 Capital Pty Ltd is not a deposit with or liability of any bank or Australian authorised deposit-taking institution (ADI). Investments are not guaranteed by Alpha Node Advisors Pty Ltd, Mondari Capital Advisors Pty Ltd, any of their related entities, or any government body. Investors may lose some or all of their invested capital.

    Any projections, forecasts, estimates, or forward-looking statements are based on assumptions considered reasonable at the time of preparation and are subject to significant uncertainty. Actual results may differ materially. Past performance is not a reliable indicator of future performance. The value of an investment and any income derived from it may go up or down.

    Read the Website Disclaimer for the full dual-licence explanation.